Projected Dividend Yield

Aeolus Pharmaceuticals is a biopharmaceutical company developing a platform of compounds in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Co.'s primary compound, AEOL 10150 (10150), is being developed under contract as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome and the delayed effects of acute radiation exposure. Co. develops 10150 for the treatment of lung fibrosis, including idiopathic pulmonary fibrosis and other fibrotic disease as well as for use in combination with radiation therapy for cancer as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control.

DividendInvestor.com features a variety of tools, articles, and resources designed to help investors interested in dividend stocks find the best dividend stocks to buy. We provide opinion articles, detailed dividend data, history, and dates for every dividend stock, screening tools, and our exclusive dividend all star rankings.